This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in


Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Treatment depends on the disease's manifestations and severity. (1)

Newly diagnosed active, severe PAN should be treated with high-dose glucocorticoids plus cyclophosphamide.

Newly diagnosed, active, non-severe PAN should be treated with glucocorticoids and other immunosuppressive agents, such as azathioprine or methotrexate.

Once remission has been obtained, non-glucocorticoid immunosuppressive agents should be continued for 18 months, alongside tapering of glucocorticoid therapy.

Tumour necrosis factor (TNF) inhibitors appear to be particularly useful in the DADA2 subtype, substantially reducing the risk of stroke.

Control of any hypertension improves prognosis.


1. Chung SA et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of Polyarteritis Nodosa. Available from:


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.


Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.